The recent acquisition of Dermavant, which brought VTAMA into Organon's portfolio, has been viewed as a strategic move to broaden the company's dermatology offerings in the U.S. market.

Analysts project VTAMA's sales potential to reach $500 million or more, contingent upon successful pediatric market penetration and patients switching from topical steroids. The recent acquisition of ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Organon , a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months ...

Update on FDA Review of VTAMA® (tapinarof ... management’s expectations regarding Organon’s recent acquisition of Dermavant Sciences Ltd. (“Dermavant”) and potential regulatory approval ...

s recent acquisition of Dermavant Sciences Ltd. (“Dermavant”) and potential regulatory approval from the FDA for the use of VTAMA® in the treatment of atopic dermatitis ...

The company expects revenue growth in 2025, including $150 million from the Dermavant acquisition. These are some of the recent developments in Organon's business operations. Organon's recent FDA ...

But two new non-steroidal topicals were introduced this year — Dermavant Science’s Vtama and Arcutis Biotherapeutics’ Zoryve — and each one solves a long-time problem plaguing millions of ...